MedPath

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Registration Number
NCT03473197
Lead Sponsor
Castle Creek Pharmaceuticals, LLC
Brief Summary

A study in healthy male and female adult volunteers to determine the potential of diacerein 1% ointment to induce a photoallergic skin reaction using a controlled photopatch testing procedure.

Detailed Description

This was a randomized, single center, vehicle controlled, within-subject comparison study of diacerein 1% ointment and vehicle ointment applied under fully occlusive patch conditions on the infrascapular region of each subject's back to induce a photoallergic skin reaction following Ultraviolet (UV) irradiation. This was repeated twice each week during the 3-week Induction Phase, once during rest week 4 as applicable and once at Challenge Phase.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
61
Inclusion Criteria
  • Is a healthy male or female (to be confirmed by medical history);
  • Is 18 years of age or older;
  • In the case of a female of childbearing potential, is using an acceptable form of birth control;
  • In the case of a female of childbearing potential, has a negative urine pregnancy test (UPT) at Day 1 and are willing to submit to a UPT at the end of study (EOS);
  • Is free of any systemic or dermatological disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs;
  • Is of any Fitzpatrick Skin Type or race, providing the skin pigmentation will allow discernment of erythema

Key

Exclusion Criteria
  • Has a history of photosensitivity or photoallergy;
  • Is using systemic/topical corticosteroids within 3 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study;
  • Is not willing to refrain from using systemic/topical anti-inflammatory analgesics such as aspirin, (occasional use of acetaminophen will be permitted);
  • Are taking medication known to cause phototoxic reactions (eg, tetracyclines, thiazides, nonsteroidal anti-inflammatory drugs [NSAIDS]);
  • Is using medication which, in the opinion of the Investigator, will interfere with the study results;
  • Is unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions or similar products on the back during the study;
  • Has psoriasis and/or active atopic dermatitis/eczema;
  • Had a known sensitivity or allergy to constituents of the materials being evaluated including diacerein, mineral oil, petrolatum, cetyl alcohol, D&C Yellow #10 and/or ethyl paraben;
  • Has damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
  • Has received treatment for any type of internal cancer within 5 years prior to study entry;
  • Has any known sensitivity to adhesives; and/or
  • Has received any investigational drugs(s) with 4 weeks prior to study entry

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single Cohort (Healthy Volunteers)Diacerein 1% ointmentDiacerein 1% topical ointment Intra-subject photoallergy (photosensitization) test
Primary Outcome Measures
NameTimeMethod
Observed Photoallergy (Photosensitization): Number of Skin Sites by Maximum Total Irritation ScoreSkin sites evaluated 24, 48, and 72 hours after patch removal and irradiation challenge

The determination of photosensitization reactions was summarized by frequency counts of the total dermal irritation score during the Challenge Phase. Total Irritation Score is a visual score summing the degree of erythema and edema. Minimum score=0, maximum score=5; higher score=worse outcome

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

TKL Research

🇺🇸

Fair Lawn, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath